We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $3B
1-Year Est. Return 46.72%
This Fund
S&P 500
This Quarter Est. Return
+0.18%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.03B
AUM Growth
+$47.9M
Cap. Flow
-$1.25B
Cap. Flow %
-41.28%
Top 10 Hldgs %
36.47%
Holding
100
New
13
Increased
18
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$79.8M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$37.4M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$34M
4
HROW icon
Harrow
HROW
+$24.8M
5
IMCR icon
Immunocore
IMCR
+$24M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$30.7M
2
TVTX icon
Travere Therapeutics
TVTX
+$30.6M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$25.7M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
26
DELISTED
HilleVax
HLVX
$26.8M 0.88%
1,620,216
– –
ACRS icon
27
Aclaris Therapeutics
ACRS
$730M
$26.4M 0.87%
3,269,094
+875,109
+37% +$11.1M
TERN
28
DELISTED
Terns Pharmaceuticals
TERN
$23.6M 0.78%
+1,997,055
New +$19.1M
ANAB icon
29
AnaptysBio
ANAB
$1.6B
$21.2M 0.7%
973,073
+246,951
+34% +$6M
IMCR icon
30
Immunocore
IMCR
$1.78B
$21.1M 0.69%
+426,110
New +$24M
DBVT
31
DBV Technologies
DBVT
$807M
$20.5M 0.67%
1,210,779
– –
ALEC icon
32
Alector
ALEC
$164M
$19.8M 0.65%
3,206,315
+2,481,291
+342% +$20.2M
SNDX icon
33
Syndax Pharmaceuticals
SNDX
$1.84B
$19.4M 0.64%
920,049
-322,753
-26% -$8.03M
GMED icon
34
Globus Medical
GMED
$10.4B
$19M 0.63%
335,200
-8,426
-2% -$540K
FNA
35
DELISTED
Paragon 28, Inc.
FNA
$18.8M 0.62%
+1,098,722
New +$19.6M
STE icon
36
Steris
STE
$20.9B
$18.3M 0.6%
95,694
– –
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.8M 0.55%
452,000
+38,400
+9% +$1.73M
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$2.37B
$16.2M 0.54%
+1,945,134
New +$18.7M
DYN icon
39
Dyne Therapeutics
DYN
$4.04B
$15.9M 0.52%
1,377,872
+624,727
+83% +$8.11M
VIR icon
40
Vir Biotechnology
VIR
$1.47B
$14.1M 0.46%
+604,036
New +$15.4M
MRSN
41
DELISTED
Mersana Therapeutics
MRSN
$13.8M 0.45%
134,232
+59,724
+80% +$8.38M
LUNG icon
42
Pulmonx
LUNG
$49.4M
$13M 0.43%
1,163,294
-458,200
-28% -$4.52M
PACB icon
43
Pacific Biosciences
PACB
$422M
$12.7M 0.42%
+1,097,300
New +$10.9M
CMPX icon
44
Compass Therapeutics
CMPX
$373M
$10.6M 0.35%
3,247,847
+1,433,581
+79% +$5.63M
ACLX
45
DELISTED
Arcellx
ACLX
$10.3M 0.34%
+333,800
New +$10.1M
ARGX icon
46
argenx
ARGX
$57.4B
$9.17M 0.3%
24,600
-24,600
-50% -$9.11M
AXNX
47
DELISTED
Axonics, Inc. Common Stock
AXNX
$9.1M 0.3%
+166,704
New +$9.74M
MLYS icon
48
Mineralys Therapeutics
MLYS
$2.35B
$8.62M 0.28%
+550,300
New +$9.26M
TMDX icon
49
Transmedics
TMDX
$2.5B
$7.46M 0.25%
98,459
-204,726
-68% -$14.2M
NUVB icon
50
Nuvation Bio
NUVB
$2.24B
$6.84M 0.23%
4,122,900
– –
1
2
3 4

Similar funds

NC
NZS Capital Denver, Colorado $3B AUM 21.29% 1-Year Est. Return
SGI
Swan Global Investments Durango, Colorado $3B AUM 15.66% 1-Year Est. Return
SP
SurgoCap Partners New York $2.99B AUM 39.34% 1-Year Est. Return
DIG
Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3B AUM 24.41% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Braidwell's Q1 2023 Portfolio in Review

As of Q1 2023, Braidwell held 100 positions worth $3.03B, up 1.6% from $2.98B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Braidwell withdrew a net $1.25B in Q1 2023, closing 19 positions and reducing 21 holdings. Its most notable exit was Travere Therapeutics, an estimated $30.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 57% a quarter earlier.

Against the trend, Braidwell opened a new position in Neurocrine Biosciences worth $77.6M.

  • Braidwell's largest Q1 2023 buy was Neurocrine Biosciences: 766,800 shares worth $77.6M.
  • Braidwell added most to Day One Biopharmaceuticals in Q1 2023, an estimated $37.4M increase.
  • Braidwell's biggest Q1 2023 reduction was Natera, cutting an estimated $30.7M.
  • Braidwell fully exited Travere Therapeutics in Q1 2023, selling an estimated $30.6M.
  • Braidwell's ten largest holdings make up 36% of its $3.03B portfolio in Q1 2023.
  • Braidwell opened 13 new positions and closed 19 in Q1 2023.
  • Braidwell's portfolio value rose 1.6% quarter-over-quarter to $3.03B.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.